148 results on '"Gul, Zartash"'
Search Results
2. Noninfectious neurologic complications of hematopoietic cell transplantation: A systematic review
3. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
4. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs
5. Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort
6. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy
7. Blinatumomab-Associated Neurological Adverse Events
8. Comparison of Intermittent Intravenous Tacrolimus to Continuous Tacrolimus in Allogeneic Stem Cell Transplant Recipients
9. Concomitant Renal Cell Carcinoma and Hematologic Malignancy in Immunosuppressed Patients
10. Post-Transplantation Management Strategies
11. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
12. High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplantation Patients
13. Sonographic Comparison of Atherosclerotic Changes in Carotid Arteries of Diabetic and Non-Diabetic Individuals
14. Abstract 6259: Molecular biomarker testing and targeted therapy patterns in patients with acute myelogenous leukemia (AML): A real-world data analysis
15. Anti-Thymocyte Globulin (Thymoglobulin), Tacrolimus, and Sirolimus as Acute Graft-versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation
16. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting
17. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia
18. Use of Type 1 Interferon-Alpha 2a for Relapse Prevention in Allogeneic Stem Cell Transplant
19. Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies
20. Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis
21. 358 - Comparison of Intermittent Intravenous Tacrolimus to Continuous Tacrolimus in Allogeneic Stem Cell Transplant Recipients
22. Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients.
23. Freeze‐dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignancies.
24. Quality Process Improvement: The Impact of Recipient Selection & Evaluation
25. Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies
26. Strongyloidiasis in the Immunocompromised—Should We Screen in Ohio?
27. Influence of rituximab and central nervous system directed prophylactic therapy on central nervous system relapse in high-risk diffuse large B-cell lymphoma
28. Blinatumomab may induce graft versus host leukemia in patients with pre‐B ALL relapsing after hematopoietic stem cell transplant
29. Immunoglobulin G4‐related disease: a rare disease with an unusual presentation
30. Evaluation of cytomegalovirus (CMV) reactivation, relapse, and survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) using two T cell depletion strategies.
31. Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period
32. 562 - Strongyloidiasis in the Immunocompromised—Should We Screen in Ohio?
33. Incidence of cardiac events in patients with MDS or AML receiving azacitidine or decitabine within a large community health system.
34. Comparison of common pretransplant assessment scores: A single institution experience.
35. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma
36. Intravenous(IV) Busulfan (BU) Pharmacokinetics Using Busulfan and Fludarabine (Flu) Conditioning in Institutions Where the Capability of Doing Pharmacokinetics Is Not Present
37. Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin’s Lymphoma Have Been Exposed To It?
38. Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention
39. Hypomethylating agents as first-line therapy in acute myeloid leukemia (AML).
40. Cytarabine plus mitoxantrone versus cytarabine plus clofarabine as second-line therapy in AML.
41. Lymphocyte Count Above 300 X 106/Ml 90 Days Post Transplant Predicts Better Overall Survival After Alemtuzumab for Unrelated Donor Stem Cell Transplant
42. Lower Lymphocyte Count At Day 30 Predicts Worse Overall Survival with Tacrolimus and Mycophenophelate Mofetil Use for Gvhd Prophylaxis: A Large Retrospective Analysis
43. EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.
44. Cardiac Toxicity After High-Dose Melphlan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
45. High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients
46. Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma
47. A Prospective Phase II Trial: The Combination of Tacrolimus, Sirolimus, and Rabbit Anti-Thymocyte Globulin (Thymoglobulin® Thymo) to Prevent Acute Graft Vs. Host Disease (aGVHD) in Patients Receiving Unrelated Hematopoietic Stem Cell Transplantation (UHSCT)
48. A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma
49. Obesity and the Risk of Non-Hodgkin's Lymphoma – A Meta-Analysis Involving More Than 40,000 Cases
50. Comparison of Clinical Outcomes and Day 30 Lymphocyte Recovery Between Two aGVHD Prophylaxis Regimens In Matched Unrelated Hematopoietic Stem Cell Transplant (MUD) Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.